Status:
COMPLETED
Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction
Lead Sponsor:
Johannes Gutenberg University Mainz
Conditions:
Esophageal Neoplasms
Stomach Neoplasms
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine the dose limiting toxicity and the maximum tolerable dose of the radiochemotherapy with Docetaxel and Oxaliplatin in patients with adenocarcinoma of the gastr...
Detailed Description
Radiotherapy starts on day 1 of chemotherapy after the application of Docetaxel and Oxaliplatin and will be administered in single doses of 1.8 Gy once daily and five times a week for 5 weeks. In the...
Eligibility Criteria
Inclusion
- adenocarcinoma of gastric-esophagal junction
- stage II to III
- unidimensional measurable disease
Exclusion
- surgery of primary tumor
- metastasis
- prior chemo- or radiotherapy
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00374985
Start Date
October 1 2005
End Date
September 1 2013
Last Update
December 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johannes-Gutenberg-Universität
Mainz, Rhineland-Palatinate, Germany, 55131